{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:11:21Z","timestamp":1789564281804,"version":"build-2803163510"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100016545","name":"Roche Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current interventions for CMV at\u2010risk recipients include leukoreduction and CMV\u2010antibody screening. We evaluated the CMV\u2010DNA prevalence in United States (US) blood donors to estimate the residual risk from cell\u2010free virus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A highly sensitive, automated quantitative nucleic acid testing (NAT) assay assessed plasma samples in pools of 24 from CMV\u2010seropositive or CMV\u2010antibody not\u2010tested donations. CMV\u2010NAT\u2010initial reactive (IR) samples were tested for CMV\u2010IgG and IgM. CMV\u2010NAT\u2010reactive donors were invited to participate in follow\u2010up (F\/U) to confirm CMV seroconversion and DNA resolution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 240,115 CMV\u2010DNA\u2010tested samples, 23 were IR; titers ranged from 34.5 to 4020\u2009IU\/mL. Of 23 IR, 20 (87%) were CMV\u2010NAT repeatedly reactive (RR); 3 (13%) were seroreactive only (repeat NAT\u2010nonreactive\/IgG\u2010only positive). Of 20 CMV\u2010NAT\u2010RRs, 4 (20%) were CMV\u2010IgG\u2010only positive, 15 (75%) were IgM\/IgG positive, and 1 (5%) was antibody\u2010negative (i.e., window\u2010period). F\/U samples from 9 RR and 2 IR\u2010only donors were collected at an 18\u2010day mean after their IR donation. All F\/U samples were NAT RR except those from the 2 IR\u2010only donors, both NAT nonreactive. F\/U IgG testing confirmed positivity in all 11 donors, with 8 of 11 also IgM positive. The mean age of CMV\u2010NAT\u2010reactive donors was 47\u2009years; 16 (70%) were male, with 6 first\u2010time donors. Previous donations (1999\u20132024) for 6 CMV\u2010reactive donors were anti\u2010CMV positive. A commercial infectivity assay yielded negative results for the 8 highest titer samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sensitive NAT determined a CMV\u2010NAT\u2010IR prevalence of 1:10,440 in plasma samples from CMV\u2010screened seropositive\/serology\u2010unscreened US blood donors. One identified window\u2010period donor highlights the limitation of current CMV interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/trf.70050","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:58:04Z","timestamp":1766577484000},"page":"376-384","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of\n                    <scp>CMV DNA<\/scp>\n                    in plasma from United States blood donors"],"prefix":"10.1111","volume":"66","author":[{"given":"Kacie","family":"Grimm","sequence":"first","affiliation":[{"name":"American Red Cross Biomedical Services Medical and Scientific Office  Washington, DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7735-8420","authenticated-orcid":false,"given":"Laura","family":"Tonnetti","sequence":"additional","affiliation":[{"name":"American Red Cross Biomedical Services Medical and Scientific Office  Washington, DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Sa\u00e1","sequence":"additional","affiliation":[{"name":"American Red Cross Biomedical Services Medical and Scientific Office  Washington, DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Roback","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine Emory University School of Medicine  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Stramer","sequence":"additional","affiliation":[{"name":"Infectious Disease Consultant  North Potomac Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"GuptaM ShormanM.Cytomegalovirus infections StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Shorman Mahmoud declares no relevant financial relationships with ineligible companies. 2025."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-77349-8_17"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/5.2.205"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-7963(91)70189-2"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(81)80662-2"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.353"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.5.2.204"},{"key":"e_1_2_9_9_1","first-page":"507","article-title":"Other virus infections in AIDS. I. Cytomegalovirus","volume":"44","author":"Drew WL","year":"1989","journal-title":"Immunol Ser"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/652438"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1086\/314939"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1086\/515277"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12199"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02486.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2005.02.002"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12250"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12366"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2014.1360"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-007-0066-x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis212"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-025-01159-6"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02036-13"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03292-15"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12437"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13605"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15751"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.70050","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.70050","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.70050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:59:04Z","timestamp":1789563544000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.70050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/trf.70050"],"URL":"https:\/\/doi.org\/10.1111\/trf.70050","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"2025-10-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}